{
    "clinical_study": {
        "@rank": "4772", 
        "acronym": "CHART-1", 
        "arm_group": [
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Sham Comparator", 
                "description": "Sham, no injection"
            }, 
            {
                "arm_group_label": "C3BS-CQR-1 Treated", 
                "arm_group_type": "Experimental", 
                "description": "Injection of C3BS-CQR-1"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluation the safety and efficacy of C3BS-CQR-1 by comparing the overall response to\n      standard of care and C3BS-CQR-1 relative to standard of care and a sham procedure."
        }, 
        "brief_title": "Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Eligible patients must meet all of the following inclusion criteria:\n\n          1. Age \u2265 18 and < 80 years.\n\n          2. Systolic dysfunction with left ventricular ejection fraction (LVEF) \u2264 35% as assessed\n             by echocardiography.\n\n          3. Ischemic heart failure without known need for revascularization.\n\n          4. Total MLHFQ score > 30.\n\n          5. Ability to perform a 6 minute walk test > 100 m and \u2264 400 m.\n\n          6. History of hospitalization for heart failure (HF) within 12 months prior to screening\n             or treatment in an outpatient clinic with intravenous vasoactive therapy (including\n             vasodilators, positive inotropic agents and vasopressors) or diuretics for worsening\n             Heart Failure within 12 months prior to screening.\n\n          7. Be or must have been within the previous 12 months in New York Heart Association\n             (NYHA) Class III or IV or Interagency Registry for Mechanically Assisted Circulatory\n             Support (INTERMACS) class 4, 5, 6 or 7, and at the time of inclusion, must be at\n             least in NYHA Class II or greater.\n\n          8. Use of ACE inhibitor and/or angiotensin receptor blocker (ARB); and beta blocker, for\n             at least 3 months prior to screening visit, unless intolerant or contraindicated.\n\n          9. Stable dosing of ACE inhibitor, angiotensin receptor blocker , beta blocker,\n             aldosterone blocker,and diuretics for at least one month prior to screening visit,\n             defined as \u226450% change in total dose of each agent.\n\n         10. Willing and able to give written informed consent.\n\n        Exclusion Criteria (summarized):\n\n        Eligible patients must meet none of the following exclusion criteria:\n\n          1. Women who are pregnant, confirmed by a positive urine or serum human chorionic\n             gonadotropin laboratory test at screening.\n\n          2. Women of child-bearing potential without a negative serum or urine pregnancy test at\n             screening.\n\n          3. Men refusing to exercise a reliable form of contraception.\n\n          4. Myocardial infarction, unstable angina or percutaneous coronary intervention (PCI)\n             within 90 days prior to screening, or coronary artery bypass graft surgery within 180\n             days prior to screening.\n\n          5. Patient on a cardiac transplant list or previously received any solid organ\n             transplant.\n\n          6. Previously underwent cardiac surgery with remodeling procedure, left ventricular\n             assist device placement or cardiomyoplasty. This exclusion does not apply to patients\n             who underwent ventricularplasty without placement device more than one year ago.\n\n          7. Patient has undergone cardiac resynchronization therapy within 6 months prior to\n             screening.\n\n          8. Severe uncontrolled HF requiring need for intensive intravenous diuretics or\n             inotropic support within 1 month prior to screening.\n\n          9. Inability to perform a 6 minute walk test due to physical limitations other than HF\n             including:\n\n               1. Severe peripheral vascular disease\n\n               2. Severe pulmonary disease or chronic obstructive pulmonary disease limiting\n                  exercise\n\n               3. Orthopedic limitations, severe muscular diseases, any other joint or muscular\n                  disease or neurological disorder (such as an old stroke or neuropathy) limiting\n                  the ability to walk for 6 minutes.\n\n         10. Dependence on chronic oral steroid therapy.\n\n         11. Stroke or transient ischemic attack leading to limitations in lower extremities or\n             occurring within 180 days prior to screening.\n\n         12. Active myocarditis, constrictive pericarditis, restrictive, hypertrophic or\n             congenital cardiomyopathy.\n\n         13. BMI < 19 or > 45.\n\n         14. Left ventricular thrombus.\n\n         15. Left ventricular (LV) wall thickness < 8mm visualized in more than 50% of LV, and\n             defined as a \"LV no-go zone\".\n\n         16. LV aneurysm or candidate for surgical aneurysmectomy.\n\n         17. Sustained ventricular tachycardia or ventricular fibrillation which led to automatic\n             implantable cardioverter/defibrillator (AICD) therapy (shock) within 3 months prior\n             to screening.\n\n         18. Primary significant organic valvular heart disease.\n\n         19. Moderate to severe aortic valve disease precluding catheter entry into the LV.\n\n         20. Mechanical prosthetic valve in aortic or mitral position.\n\n         21. Chronic infection or active malignancy.\n\n         22. Patient has compromised renal function as reflected by a serum creatinine level >3.0\n             mg/dL (>0.265 mmol/L) or is currently on dialysis.\n\n         23. Hematocrit < 28%.\n\n         24. Atherosclerosis and/or tortuosity of the aorta, iliac or femoral arteries of a degree\n             that could impede or preclude the safe retrograde passage of the delivery catheter.\n\n         25. Chronic immunosuppressive therapy due to inflammatory or systemic disease.\n\n         26. Patient tested positive for HIV 1 or 2, Hepatitis B or C, human T-cell lymphotrophic\n             virus  (HTLV) 1 or 2 (if required by regulations) or syphilis.\n\n         27. Exposure to any previous experimental cell or angiogenic therapy and/or myocardial\n             laser therapy and/or therapy with another investigational drug within 60 days prior\n             to screening or enrollment in any concurrent study that may confound the results of\n             this study.\n\n         28. Known drug or alcohol dependence or any other factors which will interfere with the\n             study conduct or interpretation of the results or in the opinion of the investigator\n             are not suitable to participate.\n\n         29. Any illness other than congestive heart failure which might reduce life expectancy to\n             less than 2 years from screening.\n\n         30. Known and relevant allergies and/or hypersensitivities to Dextran or other plasma\n             volume expanders to include Gentran, Hyskon and Macrodex."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01768702", 
            "org_study_id": "C3BS-C-11-01", 
            "secondary_id": "2011-001117-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "C3BS-CQR-1 Treated", 
                "description": "Injection of the C3BS-CQR-1 using the C-Cath\u00ae injection catheter.", 
                "intervention_name": "Injection of C3BS-CQR-1", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "Mimic the injection procedure trough insertion of a sham catheter. No injection actually performed", 
                "intervention_name": "Sham, no injection", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Chronic Heart Failure of Ischemic Origin", 
        "lastchanged_date": "January 8, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Marc.Vanderheyden@olvz-aalst.be", 
                    "last_name": "Marc Vanderheyden, MD", 
                    "phone": "+32 53 724435"
                }, 
                "facility": {
                    "address": {
                        "city": "Aalst", 
                        "country": "Belgium", 
                        "zip": "9300"
                    }, 
                    "name": "OLV Ziekenhuis Aalst"
                }, 
                "investigator": {
                    "last_name": "Marc Vanderheyden, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dariouch.dolatabadi@chu-charleroi.be", 
                    "last_name": "Dariouch Dolatabadi, MD", 
                    "phone": "+32 71 920668"
                }, 
                "facility": {
                    "address": {
                        "city": "Charleroi", 
                        "country": "Belgium", 
                        "zip": "6000"
                    }, 
                    "name": "Hopital Civil de Charleroi"
                }, 
                "investigator": {
                    "last_name": "Dariouch Dolatabadi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jo.dens@zol.be", 
                    "last_name": "Joseph Dens, MD", 
                    "phone": "+32 89 327160"
                }, 
                "facility": {
                    "address": {
                        "city": "Genk", 
                        "country": "Belgium", 
                        "zip": "3600"
                    }, 
                    "name": "Ziekenhuis Oost Limburg"
                }, 
                "investigator": {
                    "last_name": "Joseph Dens, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "vlegrand@chu.ulg.ac.be", 
                    "last_name": "Victor Legrand, MD", 
                    "phone": "+32 4 3667854"
                }, 
                "facility": {
                    "address": {
                        "city": "Li\u00e8ge", 
                        "country": "Belgium", 
                        "zip": "4000"
                    }, 
                    "name": "Centre Hospitalier Universitaire de Li\u00e8ge"
                }, 
                "investigator": {
                    "last_name": "Victor Legrand, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Antoine.Guedes@uclouvain.be", 
                    "last_name": "Antoine Guedes, MD", 
                    "phone": "+32 81 4236 28"
                }, 
                "facility": {
                    "address": {
                        "city": "Yvoir", 
                        "country": "Belgium", 
                        "zip": "5530"
                    }, 
                    "name": "CHU Mont-Godinne"
                }, 
                "investigator": {
                    "last_name": "Antoine Guedes, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Andreka.peter@kardio.hu", 
                    "last_name": "P\u00e9ter Andr\u00e9ka, MD Prof", 
                    "phone": "+36 70 382 02 70"
                }, 
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary", 
                        "zip": "1096"
                    }, 
                    "name": "Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiol\u00f3giai Int\u00e9zet - Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly"
                }, 
                "investigator": {
                    "last_name": "P\u00e9ter Andr\u00e9ka, MD Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nyolczasnoemi@gmail.com", 
                    "last_name": "Noemi Nyolczas, MD PhD", 
                    "phone": "+36 20 945 12 01"
                }, 
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary", 
                        "zip": "1134"
                    }, 
                    "name": "MH Eg\u00e9szs\u00e9g\u00fcgyi K\u00f6zpont Kardiol\u00f3giai Oszt\u00e1ly"
                }, 
                "investigator": {
                    "last_name": "Noemi Nyolczas, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "B\u00e9la Merkely, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary", 
                        "zip": "1122"
                    }, 
                    "name": "Semmelweis Egyetem - V\u00e1rosmajori Sz\u00edv- \u00e9s \u00c9rgy\u00f3gy\u00e1szati Klinika"
                }, 
                "investigator": {
                    "last_name": "B\u00e9la Merkely, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ivan.g.horvath@aok.pte.hu", 
                    "last_name": "Iv\u00e1n G. Horv\u00e1th, MD, PhD", 
                    "phone": "+36 72 536 000 35601"
                }, 
                "facility": {
                    "address": {
                        "city": "P\u00e9cs", 
                        "country": "Hungary", 
                        "zip": "7624"
                    }, 
                    "name": "P\u00e9csi Tudom\u00e1nyegyetem Klinikai K\u00f6zpont - Sz\u00edvgy\u00f3gy\u00e1szati Klinika"
                }, 
                "investigator": {
                    "last_name": "Iv\u00e1n G. Horv\u00e1th, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "amosk@barzi.health.gov.il", 
                    "last_name": "Amos Katz, MD, Prof", 
                    "phone": "+972 8 674 58 70"
                }, 
                "facility": {
                    "address": {
                        "city": "Ashkelon", 
                        "country": "Israel", 
                        "zip": "78278"
                    }, 
                    "name": "Barzilai Medical Center - Cardiology Unit"
                }, 
                "investigator": {
                    "last_name": "Amos Katz, MD, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mohamedomary@nazhosp.com", 
                    "last_name": "Muhamad Omary, MD", 
                    "phone": "+372 54 66 93 464"
                }, 
                "facility": {
                    "address": {
                        "city": "Nazareth", 
                        "country": "Israel", 
                        "zip": "16100"
                    }, 
                    "name": "Nazareth Hospital EMMS"
                }, 
                "investigator": {
                    "last_name": "Muhamad Omary, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "majdi.h@ziv.health.gov.il", 
                    "last_name": "Majdi Halabi, MD", 
                    "phone": "+972 4 682 88 44"
                }, 
                "facility": {
                    "address": {
                        "city": "Safed", 
                        "country": "Israel", 
                        "zip": "13110"
                    }, 
                    "name": "Ziv Medical Center - Heart Institute"
                }, 
                "investigator": {
                    "last_name": "Majdi Halabi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kasprzak@ptkardio.pl", 
                    "last_name": "Jaroslaw Kasprazak, MD Prof", 
                    "phone": "+48 42 653 99 09"
                }, 
                "facility": {
                    "address": {
                        "city": "\u0141\u00f3d\u017a", 
                        "country": "Poland", 
                        "zip": "91-347"
                    }, 
                    "name": "Biega\u0144ski Hospital"
                }, 
                "investigator": {
                    "last_name": "Jaroslaw Kasprazak, MD Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "seferovic@med.bg.ac.rs", 
                    "last_name": "Petar Seferovic, MD", 
                    "phone": "+381 113614738"
                }, 
                "facility": {
                    "address": {
                        "city": "Belgrade", 
                        "country": "Serbia", 
                        "zip": "11000"
                    }, 
                    "name": "Clinical Centre of Serbia, Cardiology Clinic"
                }, 
                "investigator": {
                    "last_name": "Petar Seferovic, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "branko.beleslin@gmail.com", 
                    "last_name": "Branko Beleslin, MD Prof", 
                    "phone": "+381 11 36 13 653"
                }, 
                "facility": {
                    "address": {
                        "city": "Belgrade", 
                        "country": "Serbia", 
                        "zip": "11000"
                    }, 
                    "name": "Clinical Center of Serbia - Cardiology Clinic"
                }, 
                "investigator": {
                    "last_name": "Branko Beleslin, MD Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "drarandjelovic@yahoo.com", 
                    "last_name": "Aleksandra Arandjelovic, MD Prof", 
                    "phone": "+381 60 88 39 333"
                }, 
                "facility": {
                    "address": {
                        "city": "Belgrade", 
                        "country": "Serbia", 
                        "zip": "11000"
                    }, 
                    "name": "Clinical Hospital Center Zvezdara - Cardiology Clinic"
                }, 
                "investigator": {
                    "last_name": "Aleksandra Arandjelovic, MD Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jmhg@secardiologia.es", 
                    "last_name": "Jose Maria Hernandez Garcia, MD", 
                    "phone": "+34 95 103 23 89"
                }, 
                "facility": {
                    "address": {
                        "city": "Malaga", 
                        "country": "Spain", 
                        "zip": "29010"
                    }, 
                    "name": "Hospital Clinico Universitario Virgen de la Victoria - Campus de Teatinos s/n"
                }, 
                "investigator": {
                    "last_name": "Jose Maria Hernandez Garcia, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Hungary", 
                "Israel", 
                "Poland", 
                "Serbia", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Bone Marrow-derived Mesenchymal Cardiopoietic Cells (C3BS-CQR-1) for the Treatment of Chronic Advanced Ischemic Heart Failure.", 
        "other_outcome": {
            "description": "Time to all cause mortality, time to cardiovascular mortality, and rate of worsening heart failure requiring outpatient IV therapy for heart failure or readmission for heart failure, and others.", 
            "measure": "Efficacy and safety between groups post-index procedure", 
            "safety_issue": "Yes", 
            "time_frame": "39 and 52 weeks post-index"
        }, 
        "overall_contact": {
            "email": "chomsy@c3bs.com", 
            "last_name": "Christian Homsy, MD", 
            "phone": "+32 10 39 41 00"
        }, 
        "overall_official": [
            {
                "affiliation": "Mayo Clinic, Division of Cardiovascular Diseases, Rochester (MN, USA)", 
                "last_name": "Andr\u00e9 Terzic, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "OLV Ziekenhuis Aalst (Belgium)", 
                "last_name": "Jozef Bartunek, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change between groups from baseline and 39 weeks in a hierarchical composite outcome comprising, from most to least severe outcome, days to death from any cause, number of worsening of heart failure events, change in score for the Minnesota Living with Heart Failure Questionnaire (MLHFQ) (10-point deterioration, no meaningful change,10-point improvement), change in six-minute walk distance (40-m deterioration, no meaningful change, 40-m improvement) and change in left ventricular end systolic volume (15-mL deterioration, no meaningful change, 15-mL improvement), and left ventricular ejection fraction (4% absolute deterioration, no meaningful change, 4% absolute improvement).", 
            "measure": "Efficacy between groups post-index procedure", 
            "safety_issue": "No", 
            "time_frame": "39 weeks post-index"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01768702"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Safety: Number and cause of deaths and re-admissions, number of cardiac transplantations, number of myocardial infarctions, number of strokes. Incidence of  serious adverse events (AE) through week 104 and non-serious AEs (through week 52).\nEfficacy: Time to all cause mortality, time to worsening of heart failure, and time to aborted sudden death through week 52.", 
            "measure": "Efficacy and safety between groups post-index procedure", 
            "safety_issue": "Yes", 
            "time_frame": "52 and 104 weeks post-index"
        }, 
        "source": "Cardio3 BioSciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cardio3 BioSciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}